Principal Financial Group
VTGN icon

Principal Financial Group’s VistaGen Therapeutics VTGN Stock Holding History

Principal Financial Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,017
Closed -$22.5K – 2494
2023
Q1 		$22.5K Sell
6,017
-335
-5% -$1.76K ﹤0.01% 2419
2022
Q4 		$19.6K Buy
6,352
+5,417
+579% +$20.4K ﹤0.01% 2400
2022
Q3 		$4K Buy
935
+64
+7% +$634 ﹤0.01% 2492
2022
Q2 		$23K Sell
871
-2,831
-76% -$100K ﹤0.01% 2490
2022
Q1 		$138K Sell
3,702
-1,266
-25% -$55.2K ﹤0.01% 2397
2021
Q4 		$291K Buy
4,968
+3,726
+300% +$242K ﹤0.01% 2252
2021
Q3 		$102K Buy
1,242
+269
+28% +$23.4K ﹤0.01% 2499
2021
Q2 		$92K Buy
+973
New +$72.1K ﹤0.01% 2542

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Financial Group's VTGN Position: Q2 2023 in Review

Principal Financial Group sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 6,017 shares — an estimated $22.5K sold.

Principal Financial Group first reported a position in VTGN in Q2 2021 and held it in 8 quarters. The position peaked at $291K in Q4 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Principal Financial Group reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Principal Financial Group sold 6,017 VistaGen Therapeutics shares in Q2 2023, an estimated $22.5K.
  • Principal Financial Group first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 8 quarters.
  • Principal Financial Group's VistaGen Therapeutics position peaked at $291K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Principal Financial Group's 13F filing for Q2 2023, filed 7 Aug 2023.